10.6084/m9.figshare.7981019.v1
Ke Xu
Ke
Xu
Dongkyoo Park
Dongkyoo
Park
Andrew Magis
Andrew
Magis
Jun Zhang
Jun
Zhang
Wei Zhou
Wei
Zhou
Gabriel Sica
Gabriel
Sica
Suresh Ramalingam
Suresh
Ramalingam
Walter Curran
Walter
Curran
Xingming Deng
Xingming
Deng
Additional file 7: of Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Springer Nature
2019
KRAS
Agonist
Apoptosis
Autophagy
NSCLC
Therapy
2019-04-10 05:00:00
Figure
https://springernature.figshare.com/articles/figure/Additional_file_7_of_Small_Molecule_KRAS_Agonist_for_Mutant_KRAS_Cancer_Therapy/7981019
Figure S7. Determination of single dose maximum tolerated dose (MTD). (A) Nu/Nu nude mice were treated with single dose (i.e. 0, 150 mg/kg, 300 mg/kg or 400 mg/kg) KRA-533 via i.p. (n = 6 mice per group). After treatment, the body weight of mice was measured once every other day for 2 weeks. (B) Blood analysis of mice after treatment with single dose(s) of KRA-533. (C) H&E histology of various organs from mice after treatment with single dose(s) of KRA-533. (JPG 1446 kb)